ADELAIDE, AUS, May 31, 2021 - (ACN Newswire) - Agilex Biolabs, Australia's largest and most technologically advanced
specialist bioanalytical laboratory for clinical trials is partnering with Gyros Protein Technologies and BioAnalysis
Zone to share the latest on singlicate analysis on the Gyrolab platform.
Register Here https://tinyurl.com/puwwj9zp
Singlicate analysis on the Gyrolab platform
Wednesday 2 June 2021
18:00 [EDT] 23:00 [BST] | Thursday 3 June 06:00 [CST] 08:00 [AEST]
Agilex Biolabs' Principal Method Development Scientist, Morgan Evans will present with Gyros Protein Technologies'
Application & Service Director EMEA and Asia Pacific, John Chappell for a comprehensive webinar titled Singlicate analysis on the
Gyrolab platform.
The webinar topic was inspired by the Agilex Biolabs poster presentation Development and Validation of a PK Method for
Tocilizumab in Both Singlicate and Duplicate on the Gyrolab Platform presented at the 13th EBF open symposium.
Over the last several years singlet analysis has become a hot topic within the world of LBA non-regulated and regulated
bioanalysis. A number of studies have demonstrated positive outcomes on both replicate precision assessment and PK/TK
parameters.
Due to the highly automated and robust nature of the instrument, Gyrolab has become a front runner in LBA technologies
for singlicate analysis.
This webinar will look at the overall landscape of singlet analysis and through Agilex Biolabs case studies discuss the
use of the Gyrolab technology. It will also look at how lessons learned can inform prospects of singlicate analysis on
other technological platforms keeping in mind 'speed to patient' to ensure efficiency in bioanalytical laboratories.
Agilex Biolabs' world-class laboratories feature state-of-the-art equipment including Gyrolab Xplore, MSD Quickplex 120,
Luminex Magpix, BD FACSymphony A3 flow cytometer and soon to be released, digital droplet quantitative real-time RT-PCR.
The company offers services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis
utilising the two platforms of LC-MS/MS and Immunoassay.
Australian clinical trials have remained open for business and Agilex Biolabs is a designated essential service so
clients can be assured of study continuity.
Agilex Biolabs has more than 120 staff which includes 85 dedicated laboratory staff, and supports client pharma and
biotech companies from US, Europe and APAC.
Book a confidential briefing with our scientists before you start your next clinical trial.
About Agilex Biolabs --
Agilex Biolabs, Australia's leading bioanalytical laboratory, has more than 24 years' experience in performing regulated
bioanalysis, including quality method development, method validation and sample analysis services. It has successfully
supported hundreds of preclinical and clinical trials from around the world where customers choose Australia for the
streamlined regulatory process and access to the world's most attractive R rebate of more than 40% on clinical trial work conducted in Australia. Agilex Biolabs also offers toxicology services
through its company TetraQ, an established GLP rodent toxicology facility in Australia.
Agilex Biolabs has the leading certifications including OECD GLP Recognition with NATA (Australian Government OECD GLP
Compliance monitoring authority) and ISO 17025 Accreditation for global recognition. The company has recently expanded
its main labs by more than 30% to accommodate biotech demand from APAC and the USA. Watch the new lab video walkthrough
at https://www.agilexbiolabs.com/new-labs-video
Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and
immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gyrolab, Luminex) and flow
cytometry (BD FACSymphony A3, 20 colour cell analyser).
Agilex offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology
to support immunology, cell biology and mode of action assays, including:
- Immunophenotyping
- Receptor occupancy
- Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
- PBMC assays and cellular mechanism of action assays